These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9369323)

  • 1. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
    Cudennec A; Fage D; Bénavidès J; Scatton B
    Brain Res; 1997 Sep; 768(1-2):257-65. PubMed ID: 9369323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol.
    de Bartolomeis A; Marmo F; Buonaguro EF; Rossi R; Tomasetti C; Iasevoli F
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1516-29. PubMed ID: 23357084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amisulpride: from animal pharmacology to therapeutic action.
    Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
    Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
    Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
    Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2005 Aug; 180(4):664-9. PubMed ID: 15719226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
    Möller HJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.
    Martinot JL; Paillère-Martinot ML; Poirier MF; Dao-Castellana MH; Loc'h C; Mazière B
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):154-8. PubMed ID: 8935811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain.
    Moriuchi K; Imazu Y; Yoneda H
    Neurochem Res; 1995 Jan; 20(1):95-9. PubMed ID: 7739765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Loc'H C; Mazière B; Paillère-Martinot ML
    Br J Psychiatry; 2001 Dec; 179():503-8. PubMed ID: 11731352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.